Personalised Biohacking Intelligence
Your genetic blueprint for methylation — the master regulator of DNA expression, neurotransmitter balance, detoxification, and cellular repair.
Visual overview of Sadikh's methylation cycle — showing which enzymes are functioning optimally and where genetic bottlenecks exist.
22 methylation pathway genes decoded. Each card shows Sadikh's specific genotype, functional impact, and targeted enhancers.
Reduced cystathionine beta-synthase activity — the gate to the transsulfuration pathway. This bottleneck limits glutathione ("master antioxidant") production, leaving Sadikh with lower antioxidant capacity and compromised ability to neutralise oxidative stress.
Lower methionine synthase activity — this enzyme directly converts homocysteine back to methionine. Reduced MTR function means homocysteine builds up in the bloodstream, increasing cardiovascular and cognitive risk, especially without adequate methylcobalamin.
Increased glycine N-methyltransferase activity accelerates the conversion of SAM-e to SAH — effectively burning through Sadikh's precious methyl reserves faster than they can be replenished. This reduces overall methylation potential and blunts dopamine/norepinephrine regulation.
Reduced methionine adenosyltransferase function limits the conversion of methionine into SAM-e — the universal methyl donor. Combined with GNMT over-burning SAM-e, this creates a methyl donor deficit that can impair gene expression, liver function, and neurotransmitter methylation.
Altered DNA methyltransferase activity affects how efficiently Sadikh's genome silences or activates genes via epigenetic methylation marks. This has downstream implications for cancer risk regulation, immune function, and long-term cellular ageing.
Increased MTHFS activity alters the folate cycle balance, diverting folate metabolites away from optimal methylation pathways. This creates an upstream folate utilisation issue even when folate intake appears adequate.
Heterozygous C677T variant — the most clinically studied methylation SNP. Sadikh carries one copy, reducing MTHFR enzyme efficiency by approximately 30–40%. This slows the conversion of dietary folate to active 5-MTHF, the form required for homocysteine recycling.
Secretor status variant — ABO antigens in gut mucus act as binding sites for H. pylori and other bacteria, which can reduce vitamin B12 absorption. Sadikh's FUT2 variant predisposes him to lower B12 levels, compounding the MTR gene's need for adequate methylcobalamin.
Altered folate hydrolase activity reduces the breakdown of dietary polyglutamyl-folate into absorbable free folate. Sadikh may not be extracting full folate benefit from food sources, making L-Methylfolate supplementation especially important.
High COMT activity — Sadikh efficiently breaks down catecholamine neurotransmitters (dopamine, norepinephrine). This is a strength for stress resilience, but means he may need adequate methyl donors to maintain neurotransmitter balance during high-demand periods.
Normal betaine-homocysteine methyltransferase function. This is Sadikh's backup route for homocysteine clearance via the betaine/choline pathway — critical given his MTR weakness. Betaine (TMG) supplementation can leverage this strength to compensate for his primary methylation bottleneck.
Higher MTHFD1 activity — this enzyme helps activate dietary folate and is a key part of one-carbon metabolism. Sadikh's green status here provides a useful compensatory advantage for his MTHFR heterozygosity and FOLH1 absorption issue.
Normal methionine synthase reductase function — this enzyme keeps the MTR enzyme active by regenerating its B12 cofactor. While MTR itself is weakened, having intact MTRR means the B12 recycling mechanism is functional, making B12 supplementation highly effective for Sadikh.
Clinical intelligence connecting Sadikh's genetic variants to real-world health expressions — and the interventions that matter most.
Sadikh carries a double bottleneck in his methylation engine. MTR (A2756G) reduces the enzyme that clears homocysteine back to methionine, while MAT1A (rs3851059) reduces the conversion of methionine into SAM-e. The result: less methionine coming in from homocysteine recycling, and less SAM-e being made from what methionine does exist. This creates a systemic methyl donor shortage that can manifest as low mood, cognitive fog, poor detoxification, and elevated cardiovascular risk markers.
Sadikh's CBS (C699T) variant reduces the transsulfuration pathway — the route that converts homocysteine to cystathionine and ultimately produces glutathione. With CBS running slow, his body has reduced capacity to make this master antioxidant. Combined with his GNMT variant burning through SAM-e, he is likely chronically under-producing glutathione, increasing susceptibility to oxidative damage, inflammation, and slower recovery.
Even if Sadikh supplements to increase SAM-e production, his GNMT (T/T) variant will accelerate SAM-e breakdown — like filling a bucket with a hole. This means standard supplement dosing may be insufficient. He needs both a higher intake of methyl donors and strategic co-factors (magnesium, B2) to slow the GNMT-driven depletion. Monitoring SAM-e serum levels is recommended.
Sadikh has a two-layer B12 challenge: FUT2 (G/G) predisposes him to lower gut absorption of dietary B12, and MTR (A2756G) reduces his ability to utilise it once absorbed. This is why sublingual methylcobalamin is the gold-standard choice — it bypasses gut absorption entirely. Regular B12 serum testing alone may give false reassurance; active B12 and methylmalonic acid are better markers.
Sadikh's BHMT (G/G) gene is a significant strength. The betaine/choline pathway provides an alternative, independent route for clearing homocysteine — bypassing his compromised MTR pathway entirely. By prioritising betaine (TMG), choline-rich foods, and adequate zinc, Sadikh can leverage this functional backup to significantly reduce homocysteine burden even while other pathways are under-performing.
Sadikh's MTHFR C677T (A/G) heterozygous status means synthetic folic acid is problematic — unmetabolised folic acid can accumulate and block folate receptors, worsening the very problem it's meant to solve. He must exclusively use L-Methylfolate (5-MTHF) — the active form that bypasses the MTHFR enzyme altogether. This applies to all supplements, fortified foods, and multivitamins.
Every recommendation below is directly linked to Sadikh's specific gene variants — not generic wellness advice.
| Supplement | Form / Note | Dosage | Timing | Priority | Target Gene(s) |
|---|---|---|---|---|---|
| L-Methylfolate | 5-MTHF · Never folic acid | 400–800 mcg/day | With meal | Critical | MTHFR · FOLH1 · MTHFS |
| Methylcobalamin B12 | Sublingual only · bypasses FUT2 | 1,000 mcg/day | Morning | Critical | MTR · FUT2 · MTRR |
| SAM-e | Enteric coated · empty stomach | 400 mg/day | Empty stomach AM | Critical | MAT1A · GNMT · COMT |
| Pyridoxal-5-Phosphate (P5P) | Active B6 · not pyridoxine | 20–50 mg/day | With food | High | CBS · SHMT1 |
| Betaine (TMG) | Trimethylglycine powder or caps | 1,000–2,000 mg/day | With meals | High | BHMT · MTR backup |
| Riboflavin (B2) | Standard riboflavin | 25 mg/day | With meal | Moderate | MTHFR cofactor |
| Zinc | Zinc bisglycinate preferred | 15 mg/day | Evening with food | Moderate | BHMT · MTR · folate absorption |
| Glutathione (Liposomal) | Liposomal form for absorption | 500–1,000 mg/day | Morning empty stomach | Moderate | CBS pathway compensation |
| Magnesium Glycinate | Not oxide — poor absorption | 300–400 mg/day | Evening / before bed | Moderate | MTHFR · MAT1A · COMT |
| Glycine | Powder form | 3 g/day | Pre-sleep | Supportive | GNMT · alt Hcy clearance |
Quercetin is commonly recommended in biohacking stacks for its anti-inflammatory properties. However, quercetin is a COMT inhibitor. Given Sadikh's already-compromised methyl donor status, inhibiting COMT — which relies on SAM-e for catecholamine methylation — could worsen methylation depletion and mood dysregulation. Avoid quercetin while on this methylation protocol unless specifically indicated for another condition and monitored carefully.
A staged approach ensures tolerability and allows for biomarker tracking at each phase.
Genetic predisposition is not destiny. These labs will reveal whether Sadikh's variants are actively expressing and allow precise protocol adjustments.